Login to Your Account



FINANCINGS NEWS
Aiming to step beyond the almost voodoo-like guesswork that's characterized drug development in the space, Allergen Research Corp. (ARC) plans a phase III trial with lead compound AR101 in peanut allergy.
DUBLIN – Nordic Nanovector ASA is seeking NOK400 million (US$48.7 million) in what would be the Nordic region's first significant biotech IPO of 2015.
Aura Biosciences Inc. has secured a $21 million series B round intended to carry its synthetic viral nanoparticle-based therapies into a 24-patient phase I/II ahead of planned pivotal testing for a rare ocular cancer.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: